Compare Agilent Technologies Inc (A) vs Lennar Corporation (LEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Lennar Corporation — how do they compare? Agilent Technologies Inc trades at $128.5 (market cap $37.04B), while Lennar Corporation trades at $83.65 (market cap $20.84B). The key difference: Agilent Technologies Inc is the larger of the two by market cap, and Lennar Corporation pays the higher dividend (2.31%). Which is the better fit depends on your goals.
| A | LEN | |
|---|---|---|
Market Cap | $37.04B | $20.84B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $142.40 |
52-Week Low | $110.24 | $82.30 |
Enterprise Value | $38.59B | $24.72B |
Dividend Yield | 0.78% | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Lennar (LEN) trades at $86.74, down 1.67% on the day, with a bearish technical signal despite appearing undervalued on key metrics (P/E 13.83, P/S 0.67). Recent earnings have missed expectations, with Q2 2026 EPS expected at 1.32. The company faces margin pressure as it prioritizes sales volume over price, cutting average home prices to 2017 levels to boost affordability amid high mortgage rates.
While Lennar's valuation appears attractive and analyst consensus leans bullish (46% buy ratings), near-term risks include persistent housing affordability challenges, declining profit margins, and negative cash flow trends. Execution on margin recovery through cost discipline and faster cycle times will be crucial for stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
